The increased surface levels of TIM-3 on NK cells in cancers induce NK cell impairments (61), while TIM-3 blockade results in increased NK cell cytotoxicity both in vitro and ex vivo (59, 62, 63). The gene discussed is HAVCR2; the disease is cancer.